tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
ImmunityBio’s Strategic Advancements and Market Potential Drive Buy Rating
PremiumRatingsImmunityBio’s Strategic Advancements and Market Potential Drive Buy Rating
8d ago
ImmunityBio Gains EMA Nod for ANKTIVA® in Europe
Premium
Company Announcements
ImmunityBio Gains EMA Nod for ANKTIVA® in Europe
8d ago
ImmunityBio: EMA recommends marketing authorization in EU for ANKTIVA with BCG
Premium
The Fly
ImmunityBio: EMA recommends marketing authorization in EU for ANKTIVA with BCG
8d ago
Promising Developments in ImmunityBio’s ANKTIVA for NSCLC: A Buy Rating Based on Lymphorestorative Potential and Broader Oncology Applications
PremiumRatingsPromising Developments in ImmunityBio’s ANKTIVA for NSCLC: A Buy Rating Based on Lymphorestorative Potential and Broader Oncology Applications
3M ago
Buy Rating for ImmunityBio’s ANKTIVA: Promising Phase II Results and Potential Biomarker Identification
Premium
Ratings
Buy Rating for ImmunityBio’s ANKTIVA: Promising Phase II Results and Potential Biomarker Identification
3M ago
Citizens JMP healthcare analysts hold an analyst/industry conference call
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
3M ago
ImmunityBio announces Anktiva trial
PremiumThe FlyImmunityBio announces Anktiva trial
4M ago
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
Premium
Company Announcements
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
4M ago
ImmunityBio announces early findings from QUILT-106 trial
Premium
The Fly
ImmunityBio announces early findings from QUILT-106 trial
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100